PD-L1 has been found to be associated with poor prognosis in non-small cell lung cancer (NSCLC) [20], breast cancer [21], esophageal squamous cell carcinoma [22], and urothelial carcinoma [23]. This evidence concerns the gene CD274 and breast carcinoma.